A Phase 3 Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Condition:   Myasthenia Gravis, Generalized Interventions:   Drug: zilucoplan (RA101495);   Drug: Placebo Sponsor:   Ra Pharmaceuticals Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Get up-to-date on the latest advancements in the diagnosis and treatment of myasthenia gravis.Current Opinion in Rheumatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Gangliosides are sialylated glycosphingolipids, highly abundant in our nervous system. Antibodies targeting gangliosides are usually developed as a consequence of molecular mimicry following infections. Antiganglioside antibodies are implicated in many neurological disorders such as acute and chronic polyradiculoneuropathies which includes different variants of Guillain-Barr é syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy. Presence of such antibodies in paraneoplastic peripheral neuropathy, neurodegenerative disorders, multiple sclerosis, myasthenia gravis and am...
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Review Article Source Type: research
ConclusionSurgical removal of thymoma cured myasthenia gravis in our case. We focused on proper preoperative optimization of myasthenia gravis symptoms before thymectomy.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
Immune-checkpoint inhibitors (ICIs) are novel therapeutic agents that have demonstrated relevant anti-tumor responses in multiple cancer types. They produce a potentiation of the immune response against the cancer by blocking the negative down-regulation of T cells. Checkpoint inhibitor-associated neurological side effects are rare but also potentially life-threatening [1].
Source: Neuromuscular Disorders - Category: Neurology Authors: Tags: Case report Source Type: research
The thymus plays an essential role in the pathogenesis of myasthenia gravis (MG). In patients with MG, natural regulatory T cells (nTreg), a subpopulation of T cells that maintain tolerance to self-antigens, a...
Source: Journal of Neuroinflammation - Category: Neurology Authors: Tags: Research Source Type: research
Publication date: November 2019Source: Journal of Clinical Neuroscience, Volume 69Author(s): Gao-Mei Cai, Zhe Gao, Yao-Xian Yue, Yan-Chen Xie, Xiang Gao, Hong-Jun Hao, Xian-Jun Zhang, Qi Wang, Bing Liang, Hai-Feng LiAbstractAbnormal CTLA-4 expression is involved in the development of myasthenia gravis (MG), and serum CTLA-4 levels are positively correlated with serum anti-AChR antibody concentration, which might be related with the severity of MG. Polymorphism in CTLA-4 gene is associated with various autoimmune disorders. We investigated the association of polymorphism in CTLA-4 gene with the clinical variables and severi...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Authors: Barnett C, Tabasinejad R, Bril V Abstract Introduction: Novel options for immune-based therapy in myasthenia gravis are improving the therapeutic outlook for patients. Multiple clinical trials on immunomodulation, complement inhibitors, and FcR inhibitors are providing evidence for novel immune-based therapies that promise to improve outcomes in myasthenia patients. These more focused immune treatments are reviewed in this paper.Areas covered: This paper outlines classical treatment for myasthenia gravis and then reviews recent clinical trial evidence for novel immune therapies, particularly complement inh...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
To assess the safety and efficacy of robotic extended re-thymectomy in selected refractory myasthenia gravis (MG) patients with suspected residual thymic tissue. Robotic extended re-thymectomy was performed in six MG patients with seropositive acetylcholine receptors (AChR) antibody who had undergone a previous thymectomy (one cervicotomy, two video-assisted thoracoscopic surgeries and three sternotomies). The median observation time before robotic re-thymectomy was 108 (24-171) months. The main outcomes were perioperative morbidity, mortality, conversion to open surgery and clinical outcomes according to the Myasthenia Gr...
Source: Seminars in Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: THORACIC – Original Submission Source Type: research
Condition:   Myasthenia Gravis, Generalized Intervention:   Drug: Descartes-08 Sponsor:   Cartesian Therapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Myasthenia Gravis | Research | Study